These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35530746)

  • 1. Post-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus.
    Yoshitani H; Ito J; Kozono H
    Hepat Med; 2022; 14():37-66. PubMed ID: 35530746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch
    Kozono H; Yoshitani H; Nakano R
    Int J Nephrol Renovasc Dis; 2018; 11():9-24. PubMed ID: 29391822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride.
    Akuta N; Kumada H; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K
    Hepatol Res; 2018 Jan; 48(1):45-50. PubMed ID: 28322485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.
    Kawano T; Atsukawa M; Tsubota A; Shimada N; Toyoda H; Takaguchi K; Tani J; Morishita A; Hiraoka A; Mikami S; Ishikawa T; Okubo H; Watanabe T; Okubo T; Arai T; Hayama K; Itokawa N; Kondo C; Iwakiri K
    Sci Rep; 2022 May; 12(1):7311. PubMed ID: 35508514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
    Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
    J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nalfurafine hydrochloride to treat pruritus: a review.
    Inui S
    Clin Cosmet Investig Dermatol; 2015; 8():249-55. PubMed ID: 26005355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
    Kamimura K; Yokoo T; Kamimura H; Sakamaki A; Abe S; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
    PLoS One; 2017; 12(6):e0178991. PubMed ID: 28604788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial.
    Kumada H; Miyakawa H; Muramatsu T; Ando N; Oh T; Takamori K; Nakamoto H
    Hepatol Res; 2017 Sep; 47(10):972-982. PubMed ID: 27753159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients.
    Zhang P; Xiang S; Liu B; Wang X; Yang X; Ye C; Wang Z; Li Y; Zhou L; Wang C; Li H; Huang J; Peng A; Wang X; Wang D; Xiao J; Chen W; Cheng H; Mao N; Wang J; Yang L; Chen J
    Ren Fail; 2023 Dec; 45(1):2175590. PubMed ID: 36856148
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.
    Miyamoto Y; Oh T; Aihara E; Ando A
    Handb Exp Pharmacol; 2022; 271():455-472. PubMed ID: 33201326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride.
    Yoshikawa S; Asano T; Morino M; Matsumoto K; Kashima H; Koito Y; Miura T; Takahashi Y; Tsuboi R; Ishii T; Otake H; Fujiwara J; Sekine M; Uehara T; Yuhashi K; Matsumoto S; Asabe S; Miyatani H; Mashima H
    Sci Rep; 2021 Feb; 11(1):3015. PubMed ID: 33542298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.
    Kumagai H; Ebata T; Takamori K; Muramatsu T; Nakamoto H; Suzuki H
    Nephrol Dial Transplant; 2010 Apr; 25(4):1251-7. PubMed ID: 19926718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
    Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
    Kumagai H; Ebata T; Takamori K; Miyasato K; Muramatsu T; Nakamoto H; Kurihara M; Yanagita T; Suzuki H
    Am J Nephrol; 2012; 36(2):175-83. PubMed ID: 22868684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial.
    Akuta N; Kumada H; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K
    Hepatol Res; 2018 Sep; 48(10):810-813. PubMed ID: 29601141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Related to Sleeping Disorder Due to Pruritus in Patients with Chronic Liver Disease.
    Hiraoka A; Onishi M; Koyama S; Kato M; Marui K; Murakami T; Onishi K; Adachi T; Matsuoka J; Ueki H; Yoshino T; Tsuruta M; Aibiki T; Okudaira T; Kuroda T; Iwasaki R; Suga Y; Miyata H; Ninomiya T; Hirooka M; Abe M; Matsuura B; Michitaka K; Hiasa Y
    Intern Med; 2021; 60(20):3195-3203. PubMed ID: 34657905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
    Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
    JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Opioid Pathway for Uremic Pruritus: A Systematic Review and Meta-analysis.
    Jaiswal D; Uzans D; Hayden J; Kiberd BA; Tennankore KK
    Can J Kidney Health Dis; 2016; 3():2054358116675345. PubMed ID: 28270926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.
    Wikström B; Gellert R; Ladefoged SD; Danda Y; Akai M; Ide K; Ogasawara M; Kawashima Y; Ueno K; Mori A; Ueno Y
    J Am Soc Nephrol; 2005 Dec; 16(12):3742-7. PubMed ID: 16251241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One year long-term study on abuse liability of nalfurafine in hemodialysis patients.
    Ueno Y; Mori A; Yanagita T
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):823-31. PubMed ID: 24040851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.